1. Home
  2. JBLU vs CAPR Comparison

JBLU vs CAPR Comparison

Compare JBLU & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JetBlue Airways Corporation

JBLU

JetBlue Airways Corporation

HOLD

Current Price

$5.25

Market Cap

1.5B

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$34.89

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBLU
CAPR
Founded
1998
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2002
2011

Fundamental Metrics

Financial Performance
Metric
JBLU
CAPR
Price
$5.25
$34.89
Analyst Decision
Sell
Strong Buy
Analyst Count
13
8
Target Price
$4.91
$44.63
AVG Volume (30 Days)
26.9M
946.7K
Earning Date
04-28-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
27.83
N/A
EPS
N/A
N/A
Revenue
$9,062,000,000.00
N/A
Revenue This Year
$12.11
N/A
Revenue Next Year
$6.75
$3.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.86
$4.30
52 Week High
$6.46
$40.37

Technical Indicators

Market Signals
Indicator
JBLU
CAPR
Relative Strength Index (RSI) 54.04 61.19
Support Level $4.74 $22.09
Resistance Level $5.66 $36.49
Average True Range (ATR) 0.35 2.01
MACD 0.03 0.03
Stochastic Oscillator 49.03 74.10

Price Performance

Historical Comparison
JBLU
CAPR

About JBLU JetBlue Airways Corporation

JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: